Weiss Ratings reiterated their sell (d-) rating on shares of 111 (NASDAQ:YI - Free Report) in a research report sent to investors on Saturday morning,Weiss Ratings reports.
111 Stock Down 0.6 %
Shares of YI traded down $0.06 during trading on Friday, reaching $9.80. The company's stock had a trading volume of 21,129 shares, compared to its average volume of 22,011. 111 has a twelve month low of $4.15 and a twelve month high of $14.10. The company has a market cap of $83.81 million, a price-to-earnings ratio of -2.45 and a beta of 0.46. The company has a fifty day moving average of $7.55 and a two-hundred day moving average of $7.39.
111 (NASDAQ:YI - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The company had revenue of $527.14 million during the quarter.
Hedge Funds Weigh In On 111
Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its stake in 111 by 43,619.9% in the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after acquiring an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in shares of 111 during the fourth quarter valued at about $245,000. Finally, FIL Ltd acquired a new stake in 111 during the fourth quarter worth $450,000. Hedge funds and other institutional investors own 21.32% of the company's stock.
111 Company Profile
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Featured Stories
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
